136 related articles for article (PubMed ID: 30402263)
41. Valproic Acid Enhanced Temozolomide-Induced Anticancer Activity in Human Glioma Through the p53-PUMA Apoptosis Pathway.
Tsai HC; Wei KC; Chen PY; Huang CY; Chen KT; Lin YJ; Cheng HW; Chen YR; Wang HT
Front Oncol; 2021; 11():722754. PubMed ID: 34660288
[TBL] [Abstract][Full Text] [Related]
42. Interim Results of a Phase II Study of Hypofractionated Radiotherapy with Concurrent Temozolomide Followed by Adjuvant Temozolomide in Patients over 70 Years Old with Newly Diagnosed Glioblastoma.
Yusuf M; Ugiliweneza B; Amsbaugh M; Boakye M; Williams B; Nelson M; Hattab EM; Woo S; Burton E
Oncology; 2018; 95(1):39-42. PubMed ID: 29694955
[TBL] [Abstract][Full Text] [Related]
43. Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma.
Drappatz J; Norden AD; Wong ET; Doherty LM; Lafrankie DC; Ciampa A; Kesari S; Sceppa C; Gerard M; Phan P; Schiff D; Batchelor TT; Ligon KL; Young G; Muzikansky A; Weiss SE; Wen PY
Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):85-90. PubMed ID: 20137866
[TBL] [Abstract][Full Text] [Related]
44. Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy.
Affronti ML; Heery CR; Herndon JE; Rich JN; Reardon DA; Desjardins A; Vredenburgh JJ; Friedman AH; Bigner DD; Friedman HS
Cancer; 2009 Aug; 115(15):3501-11. PubMed ID: 19514083
[TBL] [Abstract][Full Text] [Related]
45. Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG.
Blumenthal DT; Gorlia T; Gilbert MR; Kim MM; Burt Nabors L; Mason WP; Hegi ME; Zhang P; Golfinopoulos V; Perry JR; Hyun Nam D; Erridge SC; Corn BW; Mirimanoff RO; Brown PD; Baumert BG; Mehta MP; van den Bent MJ; Reardon DA; Weller M; Stupp R
Neuro Oncol; 2017 Aug; 19(8):1119-1126. PubMed ID: 28371907
[TBL] [Abstract][Full Text] [Related]
46. Phase 1 trial of ralimetinib (LY2228820) with radiotherapy plus concomitant temozolomide in the treatment of newly diagnosed glioblastoma.
Biau J; Thivat E; Chautard E; Stefan D; Boone M; Chauffert B; Bourgne C; Richard D; Molnar I; Levesque S; Bellini R; Kwiatkowski F; Karayan-Tapon L; Verrelle P; Godfraind C; Durando X
Radiother Oncol; 2021 Jan; 154():227-234. PubMed ID: 32976869
[TBL] [Abstract][Full Text] [Related]
47. JCOG0911 INTEGRA study: a randomized screening phase II trial of interferonβ plus temozolomide in comparison with temozolomide alone for newly diagnosed glioblastoma.
Wakabayashi T; Natsume A; Mizusawa J; Katayama H; Fukuda H; Sumi M; Nishikawa R; Narita Y; Muragaki Y; Maruyama T; Ito T; Beppu T; Nakamura H; Kayama T; Sato S; Nagane M; Mishima K; Nakasu Y; Kurisu K; Yamasaki F; Sugiyama K; Onishi T; Iwadate Y; Terasaki M; Kobayashi H; Matsumura A; Ishikawa E; Sasaki H; Mukasa A; Matsuo T; Hirano H; Kumabe T; Shinoura N; Hashimoto N; Aoki T; Asai A; Abe T; Yoshino A; Arakawa Y; Asano K; Yoshimoto K; Shibui S;
J Neurooncol; 2018 Jul; 138(3):627-636. PubMed ID: 29557060
[TBL] [Abstract][Full Text] [Related]
48. Hypofractionated radiotherapy with or without concurrent temozolomide in elderly patients with glioblastoma multiforme: a review of ten-year single institutional experience.
Cao JQ; Fisher BJ; Bauman GS; Megyesi JF; Watling CJ; Macdonald DR
J Neurooncol; 2012 Apr; 107(2):395-405. PubMed ID: 22105851
[TBL] [Abstract][Full Text] [Related]
49. Afatinib and radiotherapy, with or without temozolomide, in patients with newly diagnosed glioblastoma: results of a phase I trial.
Saran F; Welsh L; James A; McBain C; Gattamaneni R; Jefferies S; Harris F; Pemberton K; Schaible J; Bender S; Cseh A; Brada M
J Neurooncol; 2021 Dec; 155(3):307-317. PubMed ID: 34787778
[TBL] [Abstract][Full Text] [Related]
50. A Phase 2 Trial of Neoadjuvant Temozolomide Followed by Hypofractionated Accelerated Radiation Therapy With Concurrent and Adjuvant Temozolomide for Patients With Glioblastoma.
Shenouda G; Souhami L; Petrecca K; Owen S; Panet-Raymond V; Guiot MC; Corredor AG; Abdulkarim B
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):487-494. PubMed ID: 28011051
[TBL] [Abstract][Full Text] [Related]
51. North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme.
Sarkaria JN; Galanis E; Wu W; Peller PJ; Giannini C; Brown PD; Uhm JH; McGraw S; Jaeckle KA; Buckner JC
Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):468-75. PubMed ID: 20864273
[TBL] [Abstract][Full Text] [Related]
52. Retrospective comparison of standard and escalated doses of radiotherapy in newly diagnosed glioblastoma patients treated with concurrent and adjuvant temozolomide.
Guler OC; Yıldırım BA; Önal C; Topkan E
Indian J Cancer; 2019; 56(1):59-64. PubMed ID: 30950447
[TBL] [Abstract][Full Text] [Related]
53. Valproic acid reduces hair loss and improves survival in patients receiving temozolomide-based radiation therapy for high-grade glioma.
Watanabe S; Kuwabara Y; Suehiro S; Yamashita D; Tanaka M; Tanaka A; Ohue S; Araki H
Eur J Clin Pharmacol; 2017 Mar; 73(3):357-363. PubMed ID: 27889835
[TBL] [Abstract][Full Text] [Related]
54. Radiotherapy with or without temozolomide in elderly patients aged ≥ 70 years with glioblastoma.
Metcalfe E; Karaoglanoglu O; Akyazici E
Contemp Oncol (Pozn); 2016; 20(3):251-5. PubMed ID: 27647990
[TBL] [Abstract][Full Text] [Related]
55. Clinical and Genetic Factors Associated With Severe Hematological Toxicity in Glioblastoma Patients During Radiation Plus Temozolomide Treatment: A Prospective Study.
Lombardi G; Rumiato E; Bertorelle R; Saggioro D; Farina P; Della Puppa A; Zustovich F; Berti F; Sacchetto V; Marcato R; Amadori A; Zagonel V
Am J Clin Oncol; 2015 Oct; 38(5):514-9. PubMed ID: 24064758
[TBL] [Abstract][Full Text] [Related]
56. The added value of concurrently administered temozolomide versus adjuvant temozolomide alone in newly diagnosed glioblastoma.
Sher DJ; Henson JW; Avutu B; Hochberg FH; Batchelor TT; Martuza RL; Barker FG; Loeffler JS; Chakravarti A
J Neurooncol; 2008 May; 88(1):43-50. PubMed ID: 18231723
[TBL] [Abstract][Full Text] [Related]
57. Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme.
Athanassiou H; Synodinou M; Maragoudakis E; Paraskevaidis M; Verigos C; Misailidou D; Antonadou D; Saris G; Beroukas K; Karageorgis P
J Clin Oncol; 2005 Apr; 23(10):2372-7. PubMed ID: 15800329
[TBL] [Abstract][Full Text] [Related]
58. Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy.
Quinn JA; Jiang SX; Reardon DA; Desjardins A; Vredenburgh JJ; Friedman AH; Sampson JH; McLendon RE; Herndon JE; Friedman HS
J Neurooncol; 2009 Dec; 95(3):393-400. PubMed ID: 19533023
[TBL] [Abstract][Full Text] [Related]
59. Concurrent bevacizumab and temozolomide alter the patterns of failure in radiation treatment of glioblastoma multiforme.
Shields LB; Kadner R; Vitaz TW; Spalding AC
Radiat Oncol; 2013 Apr; 8():101. PubMed ID: 23618500
[TBL] [Abstract][Full Text] [Related]
60. Short delay in initiation of radiotherapy for patients with glioblastoma-effect of concurrent chemotherapy: a secondary analysis from the NRG Oncology/Radiation Therapy Oncology Group database.
Blumenthal DT; Won M; Mehta MP; Gilbert MR; Brown PD; Bokstein F; Brachman DG; Werner-Wasik M; Hunter GK; Valeinis E; Hopkins K; Souhami L; Howard SP; Lieberman FS; Shrieve DC; Wendland MM; Robinson CG; Zhang P; Corn BW
Neuro Oncol; 2018 Jun; 20(7):966-974. PubMed ID: 29462493
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
